|
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV Clinical research trials and Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV. Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV clinical trial. Participants frequently get the best healthcare available for their Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV  Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This study will evaluate whether the HIV vaccine ALVAC vCP1452 given in combination with interleukin-2 (IL-2) can increase immune system function in people with HIV infection.
Details: While the advent of highly active antiretroviral therapy (HAART) has contributed to the increasing control of HIV infection and viral replication, ultimate control of HIV infection will require the development of effective HIV-specific immunity in HIV infected individuals. This trial will evaluate the use of the ALVAC vCP1452 vaccine in combination with IL-2 to increase HIV-specific immune responses in HIV infected patients. ALVAC vCP1452 vaccine is a recombinant canarypox HIV vaccine that is administered as a monthly intramuscular injection. The IL-2 is self administered as a daily subcutaneous injection at a low, non-toxic dose (2 million units). Participants in this study are randomized to receive either ALVAC and IL-2 or placebo for the first 3 months of the study. During this time, participants will continue on their current antiretroviral medications and have monthly study visits. Study visits will include a brief medical interview and physical exam, administration of the vaccine, and blood tests. At the end of 3 months, participants will discontinue both their study medications (IL-2 and ALVAC or placebo) and their antiretroviral medications. This Diagnostic Treatment Interruption (DTI) will continue for a minimum of 3 months. During the DTI, participants will have weekly study visits in which viral and lymphocyte dynamics are monitored.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Single Blind, Placebo Control, Factorial Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - HIV infected - Stable HAART, defined as two or more antiretroviral drugs in combination. Changes in drugs are allowed if for any reason other than virologic failure. - CD4 cell count > 200 cells/ml for the 12 months prior to enrollment - CD4 cell count >= 400 cells/ml on two successive occasions at least 14 days apart within 30 days of study entry - HIV RNA < 2 million copies/ml, with suppression on HAART to < 50 copies/ml on two successive occasions at least 14 days apart within 30 days of entry - Acceptable methods of contraception Exclusion Criteria - Current AIDS-defining illness - Virologic failure (HIV RNA > 10,000 copies/ml) while receiving current HAART regimen - Immunomodulating agents, including interleukins; antibodies reactive with lymphocytes, monocytes, or antigen presenting cells; and polyribonucleotides - IL-2 therapy within 4 weeks of study entry - Uncontrolled active cardiac, renal, pulmonary, hepatic, or CNS disease - History of active malignancy requiring chemotherapy - History of thyroid disease or autoimmune disorders, including asthma, inflammatory bowel disease, rheumatoid arthritis, and psoriasis - Active infection with hepatitis B virus or hepatitis C virus - Severe retinopathy due to diabetes, hypertension, CMV, or macular degeneration - Serious infection or other serious medical illness that is potentially life threatening and requires systemic therapy and/or hospitalization within 14 days of study entry - Substance abuse that will compromise the participant’s ability to adhere to the study requirements - Current alcohol use of more than 1 drink/day any time during 6 months prior to study entry. One drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.25 ounces of hard liquor. - History of allergy to eggs, IL-2, or other components of the vaccine or IL-2 formulation - Pregnant or breast-feeding - Professionals working in close contact with canaries (e.g., breeding farms, bird shops)
Total Enrollment: 92
Location and Contact Information:
Overall Study Official:
KendallSmith, Principal Investigator, Cornell University Medical College
NY Presbyterian Weill Cornell Medical Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Aquanette Sass 212-746-4361
Additional Information:
Study ID Numbers: 1 R01AI51181-01A1; 0900-397
Study Start Date: March 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056797
Other Hiv Infections Studies:
1. The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
2. A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis after Effective Anti-HIV Therapy
3. The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
4. Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients
5. A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
|
|
|
|
|
|
|
|
